| scholarly article | Q13442814 |
| P356 | DOI | 10.4161/CC.11.2.19022 |
| P953 | full work available online at | http://www.tandfonline.com/doi/pdf/10.4161/cc.11.2.19022 |
| https://doi.org/10.4161/cc.11.2.19022 | ||
| https://europepmc.org/articles/PMC3293376 | ||
| https://europepmc.org/articles/PMC3293376?pdf=render | ||
| https://www.tandfonline.com/doi/pdf/10.4161/cc.11.2.19022?needAccess=true | ||
| P932 | PMC publication ID | 3293376 |
| P698 | PubMed publication ID | 22214661 |
| P5875 | ResearchGate publication ID | 51980997 |
| P50 | author | David H. Gutmann | Q56670301 |
| Jason D Weber | Q101038960 | ||
| P2860 | cites work | Inhibition of the mammalian target of rapamycin blocks epilepsy progression in NS-Pten conditional knockout mice | Q35476371 |
| mTOR complex 2 signaling and functions | Q35878519 | ||
| Dynamic regulation of the Ras pathway via proteolysis of the NF1 tumor suppressor | Q35964121 | ||
| Tuberous sclerosis complex: neurological, renal and pulmonary manifestations | Q36239644 | ||
| Ribosome biogenesis and cell growth: mTOR coordinates transcription by all three classes of nuclear RNA polymerases | Q36623674 | ||
| Expanding mTOR signaling | Q36902840 | ||
| Rapamycin (sirolimus) in tuberous sclerosis associated pediatric central nervous system tumors | Q37621405 | ||
| Everolimus for Subependymal Giant-Cell Astrocytomas in Tuberous Sclerosis | Q37806773 | ||
| mTOR Signalling in Health and Disease | Q37856364 | ||
| Control of cell survival and proliferation by mammalian eukaryotic initiation factor 4B. | Q39414084 | ||
| mTORC1 and mTORC2 regulate EMT, motility, and metastasis of colorectal cancer via RhoA and Rac1 signaling pathways | Q39571848 | ||
| The neurofibromatosis type 1 tumor suppressor controls cell growth by regulating signal transducer and activator of transcription-3 activity in vitro and in vivo. | Q39904260 | ||
| Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR | Q39961289 | ||
| Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors | Q39981784 | ||
| TORC1 is essential for NF1-associated malignancies | Q40029605 | ||
| mTORC2 activity is elevated in gliomas and promotes growth and cell motility via overexpression of rictor | Q40033644 | ||
| Regulation of the TSC pathway by LKB1: evidence of a molecular link between tuberous sclerosis complex and Peutz-Jeghers syndrome | Q41022988 | ||
| Rapamycin-induced inhibition of the 70-kilodalton S6 protein kinase | Q41608842 | ||
| The Rheb-mTOR pathway is upregulated in reactive astrocytes of the injured spinal cord. | Q41957358 | ||
| PHAS-I as a link between mitogen-activated protein kinase and translation initiation | Q42833060 | ||
| Loss of Lkb1 in adult beta cells increases beta cell mass and enhances glucose tolerance in mice | Q43266332 | ||
| The mammalian target of rapamycin as novel central regulator of puberty onset via modulation of hypothalamic Kiss1 system. | Q43280254 | ||
| Inactivation of the tuberous sclerosis complex-1 and -2 gene products occurs by phosphoinositide 3-kinase/Akt-dependent and -independent phosphorylation of tuberin | Q44516189 | ||
| Rapamycin alleviates toxicity of different aggregate-prone proteins | Q45299514 | ||
| Inhibition of mTOR signaling in Parkinson's disease prevents L-DOPA-induced dyskinesia. | Q45923687 | ||
| Proteomic analysis reveals hyperactivation of the mammalian target of rapamycin pathway in neurofibromatosis 1-associated human and mouse brain tumors | Q46417560 | ||
| Preclinical cancer therapy in a mouse model of neurofibromatosis-1 optic glioma. | Q46721093 | ||
| Drosophila S6 kinase: a regulator of cell size | Q47072437 | ||
| Nucleophosmin mediates mammalian target of rapamycin-dependent actin cytoskeleton dynamics and proliferation in neurofibromin-deficient astrocytes | Q48164011 | ||
| Neurofibromatosis-1 regulates neuronal and glial cell differentiation from neuroglial progenitors in vivo by both cAMP- and Ras-dependent mechanisms | Q80969366 | ||
| Activated CREB is sufficient to overcome inhibitors in myelin and promote spinal axon regeneration in vivo | Q80996402 | ||
| Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-beta levels in a mouse model of Alzheimer's disease | Q21136406 | ||
| Characterization of the cytosolic tuberin-hamartin complex. Tuberin is a cytosolic chaperone for hamartin | Q22010879 | ||
| Activation of mTORC2 by Association with the Ribosome | Q24294876 | ||
| Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex | Q24295120 | ||
| TSC1 sets the rate of ribosome export and protein synthesis through nucleophosmin translation | Q24297576 | ||
| Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton | Q24299873 | ||
| PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase | Q24300915 | ||
| mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery | Q24302549 | ||
| Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action | Q24302566 | ||
| Identification of Protor as a novel Rictor-binding component of mTOR complex-2 | Q24303936 | ||
| mTORC2 can associate with ribosomes to promote cotranslational phosphorylation and stability of nascent Akt polypeptide | Q24305343 | ||
| P-Rex1 links mammalian target of rapamycin signaling to Rac activation and cell migration | Q24310060 | ||
| DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival | Q24311448 | ||
| Interaction between hamartin and tuberin, the TSC1 and TSC2 gene products | Q24314470 | ||
| Nucleophosmin serves as a rate-limiting nuclear export chaperone for the Mammalian ribosome | Q24315004 | ||
| The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1 | Q24315566 | ||
| PRAS40 is a target for mammalian target of rapamycin complex 1 and is required for signaling downstream of this complex | Q24316314 | ||
| Nucleophosmin is essential for ribosomal protein L5 nuclear export | Q24322766 | ||
| Essential function of TORC2 in PKC and Akt turn motif phosphorylation, maturation and signalling | Q24323370 | ||
| Insulin-dependent stimulation of protein synthesis by phosphorylation of a regulator of 5'-cap function | Q24324452 | ||
| AMPK phosphorylation of raptor mediates a metabolic checkpoint | Q24329244 | ||
| Neurofibromatosis-1 regulates neuroglial progenitor proliferation and glial differentiation in a brain region-specific manner. | Q34206051 | ||
| Transduction of growth or mitogenic signals into translational activation of TOP mRNAs is fully reliant on the phosphatidylinositol 3-kinase-mediated pathway but requires neither S6K1 nor rpS6 phosphorylation | Q34286691 | ||
| The role of SGK1 in hormone-regulated sodium transport | Q34365414 | ||
| The p70 S6 kinase integrates nutrient and growth signals to control translational capacity. | Q34383423 | ||
| Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis | Q34508924 | ||
| mTor is required for hypertrophy of Pten-deficient neuronal soma in vivo | Q34542438 | ||
| Lkb1 regulates quiescence and metabolic homeostasis of haematopoietic stem cells | Q34679984 | ||
| The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. | Q34741372 | ||
| Germline mutations in the PTEN/MMAC1 gene in patients with Cowden disease. | Q34742581 | ||
| The S6 kinase signaling pathway in the control of development and growth. | Q34988715 | ||
| Neurofibromatosis 1: closing the GAP between mice and men. | Q35062427 | ||
| Mitogenic and nutritional signals are transduced into translational efficiency of TOP mRNAs | Q35133768 | ||
| Mammalian target of rapamycin: hitting the bull's-eye for neurological disorders | Q35157985 | ||
| Regulation of cellular growth by the Drosophila target of rapamycin dTOR | Q35206467 | ||
| Genetic and biochemical characterization of dTOR, the Drosophila homolog of the target of rapamycin | Q35206496 | ||
| Neurofibromatosis-1 regulates mTOR-mediated astrocyte growth and glioma formation in a TSC/Rheb-independent manner. | Q35229380 | ||
| Identification of FUSE-binding protein 1 as a regulatory mRNA-binding protein that represses nucleophosmin translation | Q35305016 | ||
| The Translation Initiation Factor eIF-4E Binds to a Common Motif Shared by the Translation Factor eIF-4γ and the Translational Repressors 4E-Binding Proteins | Q24336014 | ||
| Germline PTEN promoter mutations and deletions in Cowden/Bannayan-Riley-Ruvalcaba syndrome result in aberrant PTEN protein and dysregulation of the phosphoinositol-3-kinase/Akt pathway | Q24532136 | ||
| Phosphorylation of Nedd4-2 by Sgk1 regulates epithelial Na+ channel cell surface expression | Q24534668 | ||
| Repression of cap-dependent translation by 4E-binding protein 1: competition with p220 for binding to eukaryotic initiation factor-4E | Q24597361 | ||
| Phosphorylation of eucaryotic translation initiation factor 4B Ser422 is modulated by S6 kinases | Q24599204 | ||
| A novel function of the MA-3 domains in transformation and translation suppressor Pdcd4 is essential for its binding to eukaryotic translation initiation factor 4A | Q24623285 | ||
| PTEN deletion enhances the regenerative ability of adult corticospinal neurons | Q24625004 | ||
| mTOR: from growth signal integration to cancer, diabetes and ageing | Q24633662 | ||
| The proline-rich Akt substrate of 40 kDa (PRAS40) is a physiological substrate of mammalian target of rapamycin complex 1 | Q24634783 | ||
| Promoting axon regeneration in the adult CNS by modulation of the PTEN/mTOR pathway | Q24644113 | ||
| mTOR signaling: at the crossroads of plasticity, memory and disease | Q24647655 | ||
| Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling | Q24672005 | ||
| Subset of individuals with autism spectrum disorders and extreme macrocephaly associated with germline PTEN tumour suppressor gene mutations | Q24673663 | ||
| Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis | Q24681977 | ||
| RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1 | Q24682697 | ||
| FK 506-binding protein proline rotamase is a target for the immunosuppressive agent FK 506 in Saccharomyces cerevisiae | Q27931207 | ||
| Rapamycin sensitivity in Saccharomyces cerevisiae is mediated by a peptidyl-prolyl cis-trans isomerase related to human FK506-binding protein | Q27934061 | ||
| GbetaL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR | Q28115142 | ||
| p53 target genes sestrin1 and sestrin2 connect genotoxic stress and mTOR signaling | Q28117922 | ||
| A serine/threonine kinase gene defective in Peutz-Jeghers syndrome | Q28119198 | ||
| TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling | Q28131740 | ||
| Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2 | Q28181376 | ||
| Rheb binds tuberous sclerosis complex 2 (TSC2) and promotes S6 kinase activation in a rapamycin- and farnesylation-dependent manner | Q28184844 | ||
| Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases | Q28187456 | ||
| Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins | Q28207283 | ||
| Defining the role of mTOR in cancer | Q28235431 | ||
| Hypothalamic mTOR signaling regulates food intake | Q28239714 | ||
| A mammalian protein targeted by G1-arresting rapamycin-receptor complex | Q28243712 | ||
| Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34 | Q28245141 | ||
| Translational control by MAPK signaling in long-term synaptic plasticity and memory | Q28249953 | ||
| DEPTOR, an mTOR Inhibitor, Is a Physiological Substrate of SCFβTrCP E3 Ubiquitin Ligase and Regulates Survival and Autophagy | Q28251037 | ||
| Identification and characterization of the tuberous sclerosis gene on chromosome 16 | Q28257738 | ||
| mSin1 is necessary for Akt/PKB phosphorylation, and its isoforms define three distinct mTORC2s | Q28258807 | ||
| Dysregulation of the mTOR pathway mediates impairment of synaptic plasticity in a mouse model of Alzheimer's disease | Q33700331 | ||
| Disruption of the p70(s6k)/p85(s6k) gene reveals a small mouse phenotype and a new functional S6 kinase | Q33890035 | ||
| A rapamycin-sensitive signaling pathway contributes to long-term synaptic plasticity in the hippocampus | Q33898132 | ||
| Germline Inactivation of PTEN and Dysregulation of the Phosphoinositol-3-Kinase/Akt Pathway Cause Human Lhermitte-Duclos Disease in Adults | Q33905657 | ||
| cAMP- and rapamycin-sensitive regulation of the association of eukaryotic initiation factor 4E and the translational regulator PHAS-I in aortic smooth muscle cells | Q34038049 | ||
| Synthesis of the translational apparatus is regulated at the translational level | Q34058830 | ||
| Mammalian target of rapamycin (mTOR) activation increases axonal growth capacity of injured peripheral nerves | Q34107374 | ||
| Rac1 regulates the activity of mTORC1 and mTORC2 and controls cellular size | Q34176565 | ||
| Rheb promotes cell growth as a component of the insulin/TOR signalling network | Q34199893 | ||
| Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease | Q28261987 | ||
| TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth | Q28262401 | ||
| S6K1- and betaTRCP-mediated degradation of PDCD4 promotes protein translation and cell growth | Q28269583 | ||
| The LKB1 tumor suppressor negatively regulates mTOR signaling | Q28272728 | ||
| Targets for Cell Cycle Arrest by the Immunosuppressant Rapamycin in Yeast | Q28277565 | ||
| Immunopharmacology of rapamycin | Q28285198 | ||
| The mTOR pathway and its role in human genetic diseases | Q28285976 | ||
| RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs | Q28286431 | ||
| Rapamycin causes regression of astrocytomas in tuberous sclerosis complex | Q28295149 | ||
| Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells | Q28305483 | ||
| Rapamycin blocks the phosphorylation of 4E-BP1 and inhibits cap-dependent initiation of translation | Q28378802 | ||
| Protor-1 is required for efficient mTORC2-mediated activation of SGK1 in the kidney | Q28507177 | ||
| Pten regulates neuronal arborization and social interaction in mice | Q28512488 | ||
| BDNF activates mTOR to regulate GluR1 expression required for memory formation | Q28569804 | ||
| The mammalian target of rapamycin signaling pathway mediates epileptogenesis in a model of temporal lobe epilepsy | Q28579751 | ||
| The mammalian target of rapamycin complex 2 controls folding and stability of Akt and protein kinase C | Q28587901 | ||
| LKB1 is the upstream kinase in the AMP-activated protein kinase cascade | Q28610414 | ||
| Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway | Q28646919 | ||
| Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb | Q28646935 | ||
| Regulation of TORC1 by Rag GTPases in nutrient response | Q29614478 | ||
| Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome | Q29615538 | ||
| Target of rapamycin in yeast, TOR2, is an essential phosphatidylinositol kinase homolog required for G1 progression | Q29616821 | ||
| Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40 | Q29617097 | ||
| AMP-activated protein kinase induces a p53-dependent metabolic checkpoint | Q29618123 | ||
| Akt regulates growth by directly phosphorylating Tsc2 | Q29620397 | ||
| Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin | Q29620399 | ||
| Regulation of proline-rich Akt substrate of 40 kDa (PRAS40) function by mammalian target of rapamycin complex 1 (mTORC1)-mediated phosphorylation | Q30439476 | ||
| Amino acid-induced translation of TOP mRNAs is fully dependent on phosphatidylinositol 3-kinase-mediated signaling, is partially inhibited by rapamycin, and is independent of S6K1 and rpS6 phosphorylation | Q30453740 | ||
| Pharmacological inhibition of mTORC1 suppresses anatomical, cellular, and behavioral abnormalities in neural-specific Pten knock-out mice | Q30569745 | ||
| Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex. | Q30573030 | ||
| New developments in the neurobiology of the tuberous sclerosis complex | Q30583198 | ||
| A link between SIN1 (MAPKAP1) and poly(rC) binding protein 2 (PCBP2) in counteracting environmental stress | Q33358627 | ||
| Dealing with energy demand: the AMP-activated protein kinase | Q33543966 | ||
| Muscle inactivation of mTOR causes metabolic and dystrophin defects leading to severe myopathy | Q33589972 | ||
| Inhibition of the mammalian target of rapamycin signaling pathway suppresses dentate granule cell axon sprouting in a rodent model of temporal lobe epilepsy | Q33642375 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 236-248 | |
| P577 | publication date | 2012-01-15 | |
| P1433 | published in | Cell Cycle | Q1254166 |
| P1476 | title | Deconvoluting mTOR biology | |
| P478 | volume | 11 |
| Q42624833 | A Unique Herpesviral Transcriptional Program in KSHV-Infected Lymphatic Endothelial Cells Leads to mTORC1 Activation and Rapamycin Sensitivity |
| Q37419785 | A critical review of mTOR inhibitors and epilepsy: from basic science to clinical trials |
| Q28771505 | A de novo t(10;19)(q22.3;q13.33) leads to ZMIZ1/PRR12 reciprocal fusion transcripts in a girl with intellectual disability and neuropsychiatric alterations |
| Q41112215 | Actin up in the Nucleus: Regulation of Actin Structures Modulates Mesenchymal Stem Cell Differentiation |
| Q37729067 | Application and interpretation of current autophagy inhibitors and activators |
| Q26777407 | Biochemical Genetic Pathways that Modulate Aging in Multiple Species |
| Q34471534 | Bipolar disorder with comorbid binge eating history: a genome-wide association study implicates APOB. |
| Q39247363 | Branched-Chain Amino Acids and Brain Metabolism |
| Q50984727 | Bronchopulmonary dysplasia in a double-hit mouse model induced by intrauterine hypoxia and postnatal hyperoxia: Closer to clinical features? |
| Q39119180 | Clinic significance of microRNA-99a expression in human lung adenocarcinoma |
| Q26851291 | Cutting through the complexities of mTOR for the treatment of stroke |
| Q35667262 | Dexamethasone and BCAA Failed to Modulate Muscle Mass and mTOR Signaling in GH-Deficient Rats |
| Q37666497 | Dual phosphorylation of Sin1 at T86 and T398 negatively regulates mTORC2 complex integrity and activity |
| Q38302444 | Erythroid induction of K562 cells treated with mithramycin is associated with inhibition of raptor gene transcription and mammalian target of rapamycin complex 1 (mTORC1) functions |
| Q39150764 | Everolimus as second-line therapy for metastatic renal cell carcinoma: a 'real-life' study. |
| Q38777011 | Everolimus treatment in advanced solid tumors: a personal view |
| Q38840542 | GATOR1 complex: the common genetic actor in focal epilepsies |
| Q37629003 | Impacts of the mTOR gene polymorphisms rs2536 and rs2295080 on breast cancer risk in the Chinese population |
| Q54945169 | L-Arginine Enhances Protein Synthesis by Phosphorylating mTOR (Thr 2446) in a Nitric Oxide-Dependent Manner in C2C12 Cells. |
| Q37419781 | Mammalian Target of Rapamycin (mTOR) Inhibition: Potential for Antiseizure, Antiepileptogenic, and Epileptostatic Therapy |
| Q37432305 | Mammalian Target of Rapamycin (mTOR) Pathways in Neurological Diseases |
| Q26744655 | Mammalian Target of Rapamycin: Its Role in Early Neural Development and in Adult and Aged Brain Function |
| Q36100715 | Mammalian target of rapamycin signaling in diabetic cardiovascular disease |
| Q60195872 | Mechanistic Insights into PFOS-Mediated Sertoli Cell Injury |
| Q92937610 | Mechanistic target of rapamycin (mTOR) implicated in plasticity of the reproductive axis during social status transitions |
| Q39429483 | Mtor As A Potential Treatment Target For Epilepsy |
| Q34092436 | Next-generation sequencing reveals frequent consistent genomic alterations in small cell undifferentiated lung cancer |
| Q45802714 | Olaquindox disrupts tight junction integrity and cytoskeleton architecture in mouse Sertoli cells. |
| Q30438898 | Optimizing biologically targeted clinical trials for neurofibromatosis. |
| Q36432388 | Oxidant Stress and Signal Transduction in the Nervous System with the PI 3-K, Akt, and mTOR Cascade |
| Q47803583 | PIKKing a way to regulate inflammation |
| Q37228766 | Rapamycin extends life- and health span because it slows aging |
| Q38132066 | Receptor tyrosine kinase (RTK) signalling in the control of neural stem and progenitor cell (NSPC) development |
| Q27343412 | Regulation of cilium length and intraflagellar transport by the RCK-kinases ICK and MOK in renal epithelial cells |
| Q34646844 | Rictor negatively regulates high-affinity receptors for IgE-induced mast cell degranulation |
| Q33765662 | Rictor/mTORC2 facilitates central regulation of energy and glucose homeostasis |
| Q39141798 | Safety profile and treatment response of everolimus in different solid tumors: an observational study |
| Q27015640 | Shedding new light on neurodegenerative diseases through the mammalian target of rapamycin |
| Q47872951 | Sirolimus for non-progressive NF1-associated plexiform neurofibromas: an NF clinical trials consortium phase II study. |
| Q35788825 | Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a neurofibromatosis Clinical Trials Consortium phase II study. |
| Q34886859 | The mTOR signaling pathway as a treatment target for intracranial neoplasms |
| Q38096803 | The rationale of targeting mammalian target of rapamycin for ischemic stroke |
| Q49981867 | Therapeutic potential of a dual mTORC1/2 inhibitor for the prevention of posterior capsule opacification: An in vitro study |
| Q37395797 | mTOR has distinct functions in generating versus sustaining humoral immunity. |
| Q38336887 | mTOR inhibition in epilepsy: rationale and clinical perspectives |
| Q35245211 | mTOR signaling in epilepsy: insights from malformations of cortical development |
| Q35984067 | mTORC1 signaling and regulation of pancreatic β-cell mass |
| Q37407915 | mTORC2 Regulates Mechanically Induced Cytoskeletal Reorganization and Lineage Selection in Marrow-Derived Mesenchymal Stem Cells |
Search more.